Biotech Co.*

Pharma Co. (Country)

Type/Product Area

Terms/Details (Date)

Abgenix Inc. (ABGX)

AstraZeneca plc (UK)

Broad collaboration on development of fully human antibodies for up to 36 cancer targets

AstraZeneca, which gets worldwide commercialization rights, agreed to purchase $100M in Abgenix stock at $30 per share and up to another $60M in stock upon achievement of milestones; Abgenix also could get milestones of $50M for each product; there also is a co-promotion component (10/16)

Avera Pharmaceuticals Inc.*

Novartis AG (Switzerland)

License agreement under which Areva gained rights to a Phase II compound for anxiety and depression

Novartis received an undisclosed up-front payment and equity stake in Areva and could get milestone and royalty payments (10/28)

Biogen Inc. (BGEN)

Fumapharm AG (Switzerland)

License to oral therapy for second-generation fumarate derivative entering Phase III trial in Europe

Biogen gains worldwide rights except for Germany, where a first-generation product already is approved as Fumaderm (10/1)

Biota Holdings Ltd. (Australia; ASX:BTA)

Sankyo Co. Ltd. (Japan)

Collaboration pooling the flu drugs FluNet from Biota and R118958 from Sankyo

Companies will pool their long-acting influenza drugs into single pipeline, which will be available for partnerships; any revenues would be shared equally (10/3)

BioVision AG* (Germany)

AstraZeneca plc (UK)

Collaboration to discover biomarkers for inflammatory disease

BioVision will apply its phenotyping approach in the deal, terms of which were not disclosed (10/8)

BTG International Inc. (LSE:BGC)

Sankyo Co. Ltd. (Japan)

BTG acquired rights to preclinical compounds representing three approaches to treating Alzheimer's disease

Terms of the deal were not disclosed; BTG intends to continue preclinical develoment and to look for a development partner (11/6)

Cardiome Pharma Corp. (Canada; TSE:COM)

Fujisawa Healthcare Inc.

Partnership covering Cardiome's RSD1235, a Phase III drug for atrial fibrillation and flutter

Fujisawa gained rights in North America in exchange for paying $10M up front, $4M in an equity purchase, and up to $54M in development and commercial milestones; Cardiome also would get royalties (10/16)

Celera Diagnostics (joint venture of Celera Genomics Inc.; NYSE:CRA and Applied Biosystems Group; NYSE:ABI)

Merck & Co.Inc.

To identify and validate genetic markers useful in prognostic tests for certain cancers

Celera gets access to gene expression data from Merck subsidiary Rosetta Inpharmatics LLC, while Merck gets access to Celera research data useful in developing cancer drugs; terms were not disclosed (10/20)

ChemBridge Research Laboratories LLC*

GlaxoSmithKline plc (UK)

Purchase agreement under which GSK gains access to CRL's GPCR Targeted Library

Terms were not disclosed (11/18)

Chiron Corp. (CHIR)

Pfizer Inc.

Pfizer got a nonexclusive license to develop drugs against certain hepatitis C virus targets

As part of the deal, Chiron and Pfizer unit Agouron Pharmaceuticals Inc. settled patent litigation; terms were not disclosed (10/28)

CIMA Labs Inc. (CIMA)

Taiho Pharmaceutical Co. (Japan)

License to Japanese rights to CIMA's OraVescent Fentanyl for breakthrough cancer pain

Taiho licensed rights in Japan; CIMA could earn development and milestone payments, as well as revenue on sales to Taiho and royalties on sales; specific terms were not disclosed (11/12)

Corgentech Inc.*

Bristol-Myers Squibb Co.

Agreement to jointly develop and commercialize Corgentech's E2F Decoy, which is in Phase III for vein graft failure

BMS is paying $45M up front in cash and equity, and up to $205M in clinical and regulatory milestones; the companies would share rights in the U.S., and BMS would pay royalties on sales elsewhere (10/13)

CoTherix Inc.* (formerly Exhale Therapeutics Inc.)

Schering AG (Germany)

CoTherix acquired exclusive U.S. rights to Ventavis (iloprost), a synthetic prostacyclin analogue

CoTherix would pay royalties on U.S. sales; further terms were not disclosed on the product for primary pulmonary hypertension that is approved in Europe (10/14)

C Sixty Inc.*

Merck & Co. Inc.

Exclusive research license, supply agreement and commercial license option to develop drugs based on C Sixty's fullerene antioxidants

Neither terms nor the two therapeutic areas involved was disclosed (10/16)

Cyntellect Inc.*

Eli Lilly and Co.

Agreement under which Lilly will use Cyntellect technology to implement high-throughput RNAi studies to evaluate gene target function

Lilly will use the Laser Enabled Analysis and Processing technology; terms were not disclosed (10/4)

DeCode Genetics Inc. (Iceland; DCGN)

Bayer AG (Germany)

DeCode acquired an exclusive license to develop a small-molecule drug, DG031, against a target implicated in myocardial infarction

DeCode plans to initiate a Phase II trial in 2004; Bayer is eligible to receive milestone and royalty payments; the target is made by a gene isolated by DeCode (11/16)

Dharmacon Inc.*

Bayer Pharmaceuticals Corp.

Agreement under which Dharmacon will supply custom siRNA reagents to Bayer

Bayer will use the technology in target validation research; terms were not disclosed (11/11)

Dharmacon Inc.*

Rosetta Inpharmatics LLC (unit of Merck & Co. Inc.)

Collaboration to study factors affecting utility of short interfering RNA reagents for gene silencing

Dharmacon retains rights to commercialize certain discoveries from the collaboration; further terms were not disclosed (10/8)

Discovery Partners International Inc. (DPII)

AstraZeneca plc (UK)

License agreement for DPI's patents covering in vitro gene expression profiling for indicating toxicity

AstraZeneca gained nonexclusive worldwide rights; terms were not disclosed (9/25)

IBC Pharmaceuticals Inc. (subsidiary of Immunomedics Inc.; IMMU)

Schering AG (Germany)

Research collaboration to study bispecific antibodies for targeted cancer therapy

Joint research studying a Schering antibody with IBC bispecific technology; companies will share resulting technology; terms were not disclosed (10/23)

Galapagos Genomics NV* (Belgium)


Collaboration under which Galapagos will discover and validate drug targets that drive bone formation

Galapagos will use its osteoporosis know-how and SilenceSelect gene knock-down platform in the effort; Wyeth got exclusive rights to license the discoveries for osteoarthritis drug development in return for up-front, research and potential milestone payments totaling $40M (11/13)

Galapagos Genomics NV* (Belgium)

Boehringer Ingelheim GmbH (Germany)

Collaboration under which BI will use Galapagos technology to screen genes that influence viral replication

Galapagos is supplying its SilenceSelect gene knockdown platform that targets more than 4,000 druggable genes; Galapagos gets up-front access fees and could earn further option andlicense fees (11/11)

GenPath Pharmaceuticals Inc.*

Merck & Co. Inc.

Collaboration under which GenPath will use its cancer models to identify tumor- maintenance genes suitable for small-molecule development

GenPath will receive up-front and research payments, as well as potential milestones, that could total $100M; Merck gets an exclusive option to worldwide license rights, and would pay royalties on sales (11/17)

Guilford Pharmaceuticals Inc. (GLFD)

Merck & Co. Inc.

Agreement giving Guilford U.S. rights to Aggrastat (tirofiban hydrochloride) injection for platelet-mediated cardiovascular disease

Guilford is paying $84M up front as well as sales royalties until 2012; Merck will manufacture product for Guilford (10/29)

Large Scale Biology Corp. (LSBC)

Schering-Plough Animal Health Corp.

Exclusive collaboration to evaluate vaccines for the control of viral infections in animals

Large Scale will provide vaccine antigens that Schering-Plough will evaluate; the deal includes an option under which Large Scale would manufacture and supply vaccine for trials and commercialization (10/28)

MacroChem Corp. (MCHM)

Novartis AG (Switzerland)

Evaluation of product candidate combining MacroChem's SEPA technology with an undisclosed Novartis compound

Additional testing is beginning following successful completion of the first phase (10/8)

Mannkind Corp.*

Novo Nordisk A/S (Denmark)

Agreement on a feasibility study of a pulmonary formulation of a therapeutic protein using Mannkind's Technosphere delivery technology

The agreement focuses on development of an inhalable formulation of a Novo drug; terms were not disclosed (11/14)

Medarex Inc. (MEDX)

BioWa Inc. (subsidiary of Kyowa Hakko Kogyo Co. Ltd.; Japan)

Medarex licensed use of BioWa's antibody-dependent cellular cytotoxicity technology, Potelligent

Medarex has options for exclusive licenses; it will apply the technology to certain antibodies; terms were not disclosed (10/16)

Medivir AB* (Sweden; SSE:MVIR)

Jiangsu Hengrui Medicine Co. (China)

Discovery collaboration to jointly develop products for chronic obstructive pulmonary disease

The deal combined Medivir's program in protease inhibition and other technologies with Jiangsu's medicinal chemistry expertise; Jiangsu has rights to resulting products in China and Medivir in the rest of the world (11/19)

Medivir AB* (Sweden; SSE:MVIR)

F. Hoffmann-La Roche Ltd. (Switzerland)

Collaboration on a research program in the area of hepatitis C virus

Roche will provide financial support for the program and pay potential milestone and royalty payments to Medivir; Medivir retains marketing rights in the Nordic countries (11/19)

Meridica Ltd.* (UK)

Pfizer Inc.

Pfizer licensed Meridica's dry-powder inhaler, Xcelovair, for use in products for respiratory diseases

Pfizer is making an undisclosed up-front payment and could pay milestones and royalties; it also is taking an equity stake in Meridica (10/20)

MethylGene Inc.* (Canada)

Taiho Pharmaceutical Co. Ltd. (Japan)

Collaboration and license agreement for development of a small-molecule inhibitor program against histone deacetylases for cancer

MethylGene receives an up-front license fee and equity investment of $3.75M, and Taiho will fund research for at least two years and pay milestones up to $16.25M in exchange for rights in much of Asia; MethylGene retains rights elsewhere (10/20)

Momenta Pharmaceuticals Inc.*

Sandoz Inc. (unit of Novartis AG; Switzerland)

Alliance covering joint product development arising from Momenta's expertise in complex sugars and Sandoz's position in generics

Momenta would receive a share of any sales resulting from the effort; Sandoz will pay development costs and make certain other payments to Momenta (11/18)

MorphoSys AG (Germany; FSE:MOR)

Boehringer Ingelheim GmbH (Germany)

BI exercised its option to license to a therapeutic antibody in the area of inflammatory disease

The deal follows work started in February; BI will take over development of the antibody and would pay undisclosed milestone and royalty payments to MorphoSys (11/18)

Myogen Inc.*

Novartis AG (Switzerland)

Research collaboration to discover and develop drugs for cardiovascular disease

Novartis is paying undisclosed up-front fees and funding research for at least three years in exchange for the exclusive right to license targets and compounds; Myogen could get additional license fees, milestone payments and sales royalties, and has an option on certain co-promotion rights (10/13)

Neose Technologies Inc. (NTEC)

Novo Nordisk A/S (Denmark)

Two agreements to use Neose's GlycoPEGylation technology to develop three next-generation proteins

License agreements follow work begun in 2002; Neose is getting $4.3M up front and up to $51.3M in milestone payments; Novo is covering the cost of the work and would pay royalties on sales (11/17)

Neurome Inc.*


Research agreement under which Neurome will use its quantitative neuropathology know-how to help Wyeth in its CNS discovery programs

Neurome will receive research funding under the terms of the multiyear agreement (10/29)

Norwood Abbey Ltd. (Australia; ASX:NAL)

TAP Pharmaceutical Products Inc.

Exclusive license agreement giving TAP rights to Norwood's immunology technology for enhancement of an existing class of sex steroid drugs called GnRH analogues

Norwood received a $2M equity investment and could get milestone and royalty payments; the companies will explore new indications for TAP's Lupron Depot using the Norwood technology (11/11)

Peninsula Pharmaceuticals Inc. *

Takeda Chemical Industries Ltd. (Japan)

Licensing agreement on TAK-599, a preclinical broad- spectrum antibiotic from the cephalosporin class

Takeda gained a worldwide exclusive license outside Japan, and will manufacture product; terms were not disclosed (9/30)

Serenex Inc.*

F. Hoffmann-La Roche Ltd. (Switzerland)

Research agreement under which Serenex will screen Roche compounds against protein targets

Roche gets access to Serenex's Proteome Mining and Functional Proteome Fractionation technologies; terms were not disclosed (11/10)

Sunesis Pharmaceuticals Inc.*

Dainippon Pharmaceutical Co. Ltd. (Japan)

Exclusive worldwide license agreement for cancer drug SPC-595, from the naphthyridines class

Sunesis is making an undisclosed up-front payment and would pay milestones and royalties; specific terms were not disclosed (10/15)

Syrrx Inc.*

PPD Inc.

Agreement to jointly develop Syrrx-designed human dipeptidyl-IV inhibitors for Type II diabetes and other diseases

PPD invested $25M in Syrrx convertible preferred stock and will fund most of the work through Phase II; the companies would share costs of Phase III work, as well as any resulting profits; Syrrx also can earn milestone payments (11/19)

TaiGen Biotechnology Co. Ltd.* (Taiwan) Tanox Inc. (TNOX)

TTY Biopharm Co. Ltd. (Taiwan) Wyeth

Agreement to jointly develop and market a topoisomerase-I inhibitor, DB67 Agreement to develop drugs for osteoporosis based on a Tanox target gene

TaiGen will handle most of the preclinical work and TTY the later-stage work; they plan to jointly market in Asia (10/20) Wyeth will develop a small molecule against the target and Tanox will develop an antibody-based drug in parallel; Tanox will get a $1M up-front payment; other terms were not disclosed (11/13)

Transition Therapeutics Inc. (Canada; TSE:TTH)

Novo Nordisk A/S (Denmark)

Option agreement for exclusive license to TTI's Islet Neogenesis Therapy

Decision on option is expected in 3Q:04; Novo paid $500,000 and would pay $5 million up front in license and equity fees and up to $51.5M more in milestone payments if it exercises option, along with commercial milestones and royalties (11/7)

Vion Pharmaceuticals Inc. (VION)

Beijing Pason Pharmaceuticals Inc. (China)

Exclusive license to Triapane for anticancer and antiviral uses in China

Vion will get $500,00 up front and milestone payments up to $4.75M, as well as royalties of 11% on sales in China (10/21)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

ASX = Australian Stock Exchange; FSE: Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSE: Toronto Stock Exchange.